Indena logo
Welcome to www.soyselect.info

Bookmark and Share

Extensive in vivo and in vitro experimental trials have been carried out on Soyselect® to provide a complete pharmacological profile.

In vivo

estrogenic activity in animal models of menopause (1-4):

Soyselect® in the immature rat uterotrophic assay has shown no effect, leaving unchanged uterine weight when compared to controls.

Soyselect® in the ovariectomized rat (OVX) model of menopause produced a bone-sparing effect associated with a slowing down in the increased bone turnover observed after ovariectomy (as indicated in table 1 by measurements of serum osteocalcin levels and urinary excretion ratio of deoxypyridinoline, DPD). Organ weight data and histopathological analysis did not show any stimulatory activity of Soyselect® on the uterus, thus suggesting a tissue specific response.

Bone-related parameters in rats after treatment

Table 1: bone-related parameters in rats after treatment
with SOYSELECT® or 17-ß estradiol

anticancer activity (5-8):

the chemopreventive effect of Soyselect® has been evaluated on 7,12-dimethylbenz[a]anthracene (DMBA) induced mammary tumors in rats. Only tumors classified as adenocarcinomas were considered for data evaluation. In treated animals, mammary tumors took a longer period of time to develop, with a dose-dependent percentage reduction of poorly differentiated tumors.

In an other animal study on Soyselect®, Gallo et al., have shown that soy phytochemicals slow the in vivo growth of Nonsmall Cell Lung Cancer xenografts suggesting that direct or indirect modulation of Akt signaling pathways may have a role in the activity observed. This study provides further support for the concept that consumption of phytoestrogens may be effective in delaying lung cancer progression.

antiangiogenic activity (9):

Soyselect® has been proven effective in inducing a significant inhibition of angiogenesis caused by means of basic Fibroblast Growth Factor (bFGF) in athymic nude mice.

In vitro

antioxidant activity (10-12):

Soyselect® and its isoflavone fraction has been evaluated by means of different experimental models (cells free, membrane and cell systems).

cardiovascular protective activity (13-14):

Soyselect® isoflavone fraction has been evaluated for the inhibiotn of polymorphonuclear leukocytes (PMN) adhesion to activated platelets or endothelial cell lining on the injured vascular wall. This mechanism is involved in the inflammatory process and tissue damage characteristic of some pathological situation such as reperfusion injury, atherosclerosis and thrombosis.

(1) Report Pharm/04/03 - Indena S.p.A., Internal File.
(2) Report Pharm/05/03 - Indena S.p.A., Internal File.
(3) Gallo D., Zannoni G.F., Apollonio P., Martinelli E., Ferlini C., Passetti G., Riva A., Morazzoni P., Bombardelli E., Scambia G., "Characterization of the pharmacologic profile of a standardized soy extract in the ovariectomized rat model of menopause: effects on bone, uterus, and lipid profile", Menopause Sep-Oct;12(5):589-600 (2005).
(4) Report Pharm/08/03 - Indena S.p.A., Internal File.
(5) Report Pharm/03/98 - Indena S.p.A., Internal File.
(6) Gallo D., Giacomelli S., Cantelmo F., Zannoni G.F., Ferrandina G., Fruscella E., Riva A., Morazzoni P., Bom-bardelli E., Mancuso S., Scambia G., "Chemoprevention of DMBA-induced mammary cancer in rats by dietary soy", Breast Cancer Res. Treat. Sep;69(2):153-64 (2001).
(7) Gallo D., Ferrandina G., Giacomelli S., Fruscella E., Zannoni G.F, Morazzoni P., Riva A., Bombardelli E., Mancuso S., Scambia G., "Dietary soy modulation of biochemical parameters in DMBA-induced mammary tumors", Cancer Lett. Dec 1;186(1):43-8 (2002).
(8) Daniela Gallo, Gian Franco Zannoni, Ilaria De Stefano, Marco Mosca, Cristiano Ferlini, Elisabetta Mantuano and Giovanni Scambia, “Soy Phytochemicals Decrease Nonsmall Cell Lung Cancer Growth In Female Athymic Mice”, J Nutr. Jul;138(7):1360-4 (2008).
(9) Report Pharm/20/02 - Indena S.p.A., Internal File.
(10)
Report Istituto Chimico e Tossicologico dell’ Università degli Studi di Milano, 24 September 1999 - Indena S.p.A., Internal File.
(11) Report Istituto Chimico e Tossicologico dell’Università di Milano, 7 December 2000 - Indena S.p.A., Internal File.
(12) Maffei Facino R., Carini M., Aldini G., Piccone M., Morazzoni P., Bombardelli E., Joint Meeting of the ASP, AFERP, GA and PSE 1999, 2000 Years of Nat. Prod. Res. “Past, Present and Future”, July 26-30, Amsterdam, 1999.
(13) Report Consorzio Mario Negri Sud, 22 June 2001 - Indena S.p.A., Internal File.
(14) Rotondo S., Totani L., Manarini R., Piccoli A., Martelli N., Pecce R., Riva A., Morazzoni P., Evangelista V., Food & Nutrition for Better Health, 13-15 June 2001, Santa Maria Imbaro - Lanciano, Italy.

BACK

 

Get Adobe Reader

Privacy Notice
Copyright © 2009 Indena S.p.A. All rights reserved
Indena S.p.A .tel.+39.02.574961 fax+39.02.57404620
p.i. 04411780150